We are live on ! Find out more
XTNT icon

Xtant Medical Holdings
XTNT

21 hedge funds and large institutions have $2.39M invested in Xtant Medical Holdings in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

24% more funds holding

Funds holding: 17 → 21 (+4)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

41% less capital invested

Capital invested by funds: $4.03M → $2.39M (-$1.64M)

Holders
21
Holders Change
+4
Holders Change %
+23.53%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
3
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
+$84.8K
2
GCM
Goldman Capital Management
New York
+$81.8K
3
Renaissance Technologies
Renaissance Technologies
New York
+$33.3K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$28.1K
5
Citadel Advisors
Citadel Advisors
Florida
+$28K

Top Sellers

Rank Fund Capital Flow
1
PCM
Perkins Capital Management
Minnesota
-$181K
2
BA
Bard Associates
Illinois
-$74.2K
3
TYCC
Texas Yale Capital Corp
Florida
-$19K
4
UBS Group
UBS Group
Switzerland
-$8.41K
5
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCM
1
Goldman Capital Management
New York
$1.04M +$81.8K +4,446 +6%
O
2
OrbiMed
New York
$537K – – –
PCM
3
Perkins Capital Management
Minnesota
$334K -$181K -9,854 -29%
OA
4
Outfitter Advisors
Virginia
$143K – – –
BA
5
Bard Associates
Illinois
$89K -$74.2K -4,033 -38%
VKH
6
Virtu KCG Holdings
New York
$63K +$84.8K +4,609 New
UBS Group
7
UBS Group
Switzerland
$42K -$8.41K -457 -13%
Renaissance Technologies
8
Renaissance Technologies
New York
$25K +$33.3K +1,808 New
Citadel Advisors
9
Citadel Advisors
Florida
$21K +$28K +1,523 New
Goldman Sachs
10
Goldman Sachs
New York
$20K +$27K +1,468 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$20K +$28.1K +1,525 New
Cambridge Investment Research Advisors
12
Cambridge Investment Research Advisors
Iowa
$18K – – –
WEC
13
Winslow Evans & Crocker
Massachusetts
$17.1K – – –
Morgan Stanley
14
Morgan Stanley
New York
$10K -$386 -21 -3%
FHA
15
First Horizon Advisors
Tennessee
$3K +$6.13K +333 New
AG
16
Advisor Group
Arizona
$2K – – –
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$2K – – –
Citigroup
18
Citigroup
New York
$1K – – –
BFA
19
BlackRock Fund Advisors
California
$1K +$221 +12 +13%
Bank of America
20
Bank of America
North Carolina
$1K +$1.2K +65 +2,167%
TYCC
21
Texas Yale Capital Corp
Florida
– -$19K -833 Closed
TRCT
22
Tower Research Capital (TRC)
New York
– -$1K -39 Closed

XTNT Hedge Fund Activity: Q3 2016 in Review

21 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Xtant Medical Holdings (XTNT) for Q3 2016, worth a combined $2.39M — down 41% from $4.03M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new XTNT positions and 2 closed out — a net gain of 4 holders — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $84.8K. The largest seller was Perkins Capital Management, cutting an estimated $181K.

  • 21 institutional investors held Xtant Medical Holdings (XTNT) as of Q3 2016, up from 17 in Q2 2016.
  • Funds reported $2.39M of Xtant Medical Holdings stock for Q3 2016, down 41% quarter-over-quarter.
  • 6 funds opened new Xtant Medical Holdings positions in Q3 2016 and 2 closed out, a net change of +4 holders.
  • The largest Xtant Medical Holdings buyer in Q3 2016 was Virtu KCG Holdings, an estimated $84.8K added.
  • The largest Xtant Medical Holdings seller in Q3 2016 was Perkins Capital Management, an estimated $181K sold.

Based on aggregated 13F filings for Q3 2016.